John is a drug discovery scientist with over a decade of experience designing molecules for complex therapeutic targets. He has significant experience with various screening methodologies including DEL, covalent, and fragment based approaches; prior to Inductive, he led a molecular design team focused on validating hits generated from the screening platform at Terray Therapeutics. John got his start in industry at Amgen, where he worked across multiple therapeutic areas culminating in leading the chemistry team that discovered AMG193, a PRMT5 oncology asset that reached Phase II. John then brought his late-stage optimization skills to MOMA Therapeutics where he contributed to the efficient discovery of multiple clinical candidates. As a Medicinal Chemist at Inductive, John applies his passion for structure based design, computation, and synthetic chemistry to drug discovery. Outside of work, you'll find him cooking and chasing his kids.